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Introduction  
“Knowing is not enough; we must apply. Willing is not 
enough; we must do.” Goethe 
Scientists and academic researchers have put forward a 
myriad of novel insights and technologies that can revo-
lutionise patient care. But the challenge lies in bringing 
such valuable work to bedside practice. According to 
the WHO commission statement on intellectual property 
rights, innovation cycle involves a cycle of three se-
quential defined stages- discovery, development and 
delivery [1]. This sequence of innovation-translation 
cycle is a dynamic process which involves complex 
multi-factorial interaction of factors such as intellectual 
coherence, scientific validity, resource availability, so-
cio-cultural acceptance, political influence and so on. 
These factors determine the successful translation of a 
novel innovation into medical practice to the benefit of 
the patients. The innovation-translation cycle does not 
possess an accurately defined infrastructure. Rather it is 
an uncoordinated process that enables the delivery of 
medical innovations to the patients which characteristi-
cally takes two to three decades of time [2]. This article 
presents an outline of innovation-translation models, a 
perspective on the factors and barriers influencing inno-
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vation translation and future directions for smooth, un-
disputed transition of medical innovations into market 
products. 
The process of innovation begins as a basic research in 
an academic institution which then diffuses among the 
stakeholders of medical industry where a minimally 
amplified preclinical analysis through application on 
experimental setup such as in vitro studies, on animal 
models or computational models is carried out to ensure 
the viability of the deemed innovation. The segment of 
cycle between the emergence of innovation and the dif-
fusion into medical industry is termed the valley of 
death where most innovations fade. The medical indus-
try in contract with the academic institutions or organi-
sations initiate targeted development through clinical 
trails which if successful is followed by manufacturing 
and marketing. The marketed product then diffuses 
among the healthcare professionals who are the final 
evaluators of the innovation. Adoption into practice is 
followed by post-marketing analysis of efficiency and 
feedback. Multiple factors affect the progress of innova-
tion in every step which should to be specifically ad-
dressed for successful translation. 
Linear Vs Novel cyclic dynamic model of innovation 
translation 
According to Everette Roger, the process of innovation 
assimilation follows a linear pathway involving five 
steps- knowledge, persuasion, decision, implementation 
and confirmation [3]. On the basis of the above model, 
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 the spread of innovation forms a S-shaped curve when 
cumulative distribution of adopters was plotted against 
time (Figure 1). This model of innovation translation 
provides the user with just two options- either to adopt 
or to reject. Hence, this linear model was criticised by 
many as over simplification of a much complex phe-
nomenon [4, 5]. Adoption is the beginning of post-
adoption analysis of the innovation that enables default 
recognition, contextual redesigning, feedback and reno-
vation. Following adoption, the innovation undergoes a 
significant problem-solution sequence which motivates 
further research to re-explore the indications and utility, 
and drives the efforts for further innovation with better 
performance and low cost. Hence, the innovation-
translation cycle is a perpetual dynamic cyclical process 
of invention or discovery, diffusion, adoption, post-
adoption analysis, exploration and renovation (Figure 
2). This cyclic dynamic model of innovation-translation 
is more scientifically and sociologically acceptable 
since it ensures continuous drive for innovation and 
subsequent assimilation i.e. self-perpetuating innovation
-translation cycle. It also initiates the chain of long-term 
learning through constant exchange of feedback be-
tween the innovators, developers and adopters which 
gradually minimises the degree of uncertainty associat-
ed with the innovation and also enables the conceptuali-
sation of a new technology with superior performance 
and reduced costs. 
Determinants of innovation translation 
The spread and adoption of an innovation in medical 
practice are determined by the characteristics of the 
innovation, the involvement of stakeholders, socio-
cultural factors, and the materialistic resources for in-
stallation and commissioning the innovation. Transla-
tion can either be an informal horizontal diffusion of the 
innovation by the users or formal, active, planned, poli-
cy-driven dissemination.  The determinants of the de-
gree of translation can be explained as scientific and 
conceptual determinants, socio-political factors, re-
source availability and the role of stakeholders. 
Scientific and Conceptual determinants 
Conceptual determinants depend on the scientific and 
conceptual basis of the innovation, implementation and 
maintenance. The attributes of innovation such as the 
scientific ground, validity, clinical utility, intensity of 
use of existing vs new technology, the scope of expan-
sion, adaptability, degree of demand, performance, du-
rability, cost-effectiveness and skill set requirement 
form major determinants. Strength of evidence for adop-
tion, context of implementation, measures of perfor-
mance, indices for quality assessment, availability of 
feedback mechanisms, accessible service facilities and 
associated risk for user and operator are also significant 
determinants. The uncertainty and vulnerability of a 
recently implemented innovation are critical characteris-
tics that impact diffusion. The process of development 
of an innovation and diffusion of a medical technology 
requires cross-disciplinary involvement and coordina-
tion which in turn requires a strong articulation of 
thoughts, ideas and principles among the multidiscipli-
nary members for efficient execution. 
Socio-political factors 
The political factors that influence innovation diffusion 
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 are allocation of public funds, recruitment of regulatory 
body, regulatory and investment policies, incentivised 
research and development, active propaganda of innova-
tion, and monitoring investment. Sociological determi-
nants influence the progress of innovation at every stage
- discovery, development, diffusion and delivery. Inter-
professional alliance and interpersonal communication 
are major determinants since decisions emerge through 
informal discussions, patterns of friendship, advice and 
communication. It should also be noted that a high vol-
ume of medical innovations (such as magnetic reso-
nance, ultrasound, lasers, modern monitors, electronic 
controlled infusion pumps, fiberoptics, laparoscopy 
cameras, etc) have emerged not out of biomedical re-
search but through the transfer of technology and princi-
ples from other fields. Inter-organizational coordination, 
social acceptance, expectation of the public, effect on 
existing healthcare systems and practices, involvement 
of networks for changes, situation and economic status 
of the adopter, competence of the stakeholders and tra-
ditional attitude of the targeted users are the sociological 
factors that collectively affect the innovation-translation 
cycle. The dynamicity of medical innovation-translation 
cycle can also be attributed to intimate interactions be-
tween the innovator, developer and the user, the depend-
ency of the progress of innovation-translation on the 
political climate, financial policies and the evolution of 
medical speciality. 
Resource availability 
Resources include financial and human resources. Fi-
nancial resources possess a critical hold over every step 
of the innovation-translation dynamics. It is essential for 
any innovation to emerge, for the generation of first 
evidence of innovation, for further preclinical and clini-
cal experimenting and for propagation. Affordability is 
a significant factor that influences innovation diffusion. 
Quantitative and qualitative adequacy of manpower 
affects the successful translation of innovation. Compe-
tence of the developer and user, user skillset, capability 
of the operator to utilise, re-explore the innovation and 
renovate, and the capability of regulatory bodies to gen-
erate policies are few of the important qualitative human 
factors that influence innovation translation. A state of 
balance between demand and delivery of technology 
favours further innovation.  
Role of stakeholders 
Stakeholders possess a significant contribution in the 
translation of innovation. Stakeholders involved are 
innovators, manufacturers, distributors, international 
and domestic regulators, adopters (healthcare profes-
sionals like doctors, nurses and other health workers) 
and beneficiaries (patients and researchers). Throughout 
the sequence of innovation-translation cycle, the compe-
tence and skillset of the stakeholders, their interests and 
involvement and their ability to exploit, evaluate and 
redesign the innovation play a vital role in determining 
the degree and quality of innovation diffusion and utili-
sation. They also influence the rate and direction of fur-
ther research, development and evolution of technology. 
Configurational type of national innovation policies 
Brown N et al [6] classified configurations as “close 
knit” and “loose knit” based on their organisation and 
regulatory compliance. Close knit configuration is 
standard, highly strategic, stable, with complex interac-
tion of organisations demanding high resources and 
possess robust regulatory measures. While loose knit 
configuration is characterised by simple, weak networks 
demanding low resources with optimal to suboptimal 
regulation. Close knit configuration resists innovation 
due to the complexity of translation and stability where-
as loose knit configuration favours innovation owing to 
its flexibility. 
Mandate and barriers: An Indian perspective 
With a motive to make Universal Health Coverage a 
reality, Healthcare system in India is facing a crisis due 
to healthcare inflation, lack of resources, increased dis-
ease burden and insufficient manpower. The govern-
ment is trying to address healthcare inflation by irration-
ally cutting down the healthcare costs which will in turn 
reduce the quality of care and will discourage invest-
ment. Moreover, owing to out-of-pocket payment for 
healthcare services, inflation will cause catastrophic 
events in the socioeconomic domain of the nation. This 
throws the Indian healthcare system in need of innova-
tions in every aspect- regulations, policies, devices, di-
agnostics and therapeutics. In spite of this urgent need 
the process of innovation is posed with multiple barri-
ers, a few of which are listed below. 
 Lack of local research tradition and drive. 
 Sub-competent education, lack of aptitude and skill. 
 Emigration of trained and skilled professionals due 
to absence of competitive environment for biomedi-
cal research. 
 Inadequate local and public investment. 
 Dependence on developed nations and international 
NGOs for financial support. 
 High dependence on developed nations for innova-
tions while only a minor degree of reverse innova-
tion occurs within the nation. 
 Lack of data and evidence regarding existing health 
demand to drive innovation. 
 Poor innovator-developer-user interaction. 
 Inadequate resources, motivation and guidance for 
commercialisation and translation. 
 Lack of efficient regulatory body to monitor, evalu-
ate and approve innovations. 
Challenges and future directions 
“ It's easy to make perfect decisions with perfect infor-
mation. Medicine asks you to make perfect decisions 
with imperfect information.” 
Siddhartha Mukherjee, The laws of Medicine  
The process of innovation and subsequent assimilation 
is influenced by a variety of factors such as political 
climate, financial resources, innovator-developer-user 
interaction, user aptitude, community demand and so 
on. A multi-pronged initiative that would collectively 
address each of the factor would be an ideal interven-
tion.  
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 Political and Economical reforms 
The recent reforms of the Government of India to em-
phasis the significance of Universal Health Coverage to 
improve the quality of life of the citizens is highly ap-
preciated by the global health industry. The government 
aims to attain this goal by substantially increasing the 
healthcare investment, bold policies and meticulous 
regulation. An example of the recent applauded reforms 
would be Ayushman Bharat which will provide an in-
surance benefit of 5 lakhs per family per year for 40 
percentage of Indian population. But the recent cuts on 
the healthcare costs as a price control measure will dis-
courage innovation assimilation. Though the govern-
ment intended to reduce the overall healthcare expendi-
ture and to improve access to healthcare, it unfortunate-
ly resulted in marked reduction in investment in re-
search and development, reduction in the quantity and 
quality of production and promoted illegal trades. A 
stable business ecosystem is neither formed by extreme 
profitability nor by charity but by a balance between the 
both. A promising reform would be generate legislations 
and policies that obliterate hidden indirect costs such as 
middleman margins, difference in wholesale price and 
retail price and corruption which are responsible for 
healthcare cost inflation. Measures to rationalise the 
cost of medical interventions such as Trade Margin Ra-
tionalisation (TMR) and rewarding patient-friendly in-
novators would be fruitful. The government should also 
ensure the companies a fair return on investment which 
can further be invested in research and development. 
Funding of innovations should be done on priority on 
the basis of factors such as- demand, utility, expected 
impact and cost-effectiveness. If the performance of 
certain innovations can provide a solution, then active 
dissemination should be ensured by supporting with 
strong market and policy reforms.  
Innovation studies   
Innovations are highly dynamic, proceed in unpredicta-
ble tracks and mutate throughout the process [7]. These 
attributes of innovation need specific exploration by 
scientific, process-oriented, stepwise, rational approach-
es. Innovations are described by proximal and distal 
study approaches. Innovation studies are directed to 
understand the rationale, predict the course of innova-
tion, measure efficiency,  describe characteristics such 
as social configuration, organisational phenomena, and 
the collection of interests, desires and power that enable 
innovation and to imply the acquired knowledge to di-
rect the future endeavours. Innovation studies are essen-
tial due to the existing gap between scientific advance-
ment and regulatory policies and to reduce the uncer-
tainty that dominates decision-making. Efforts are made 
to publicise only the successful innovations while the 
details of failed innovations lay hidden, owing to which 
ascertaining the predictors of success or failure remains 
a questionable task. Hence, efforts should also be made 
to analyse and determine the cause of failure. 
Double-road innovation and Novel Business models 
Introduction of any new technology in to the healthcare 
market has a certain degree of demand among the users. 
It can be assumed that the distribution of degree of de-
mand follows normal distribution. On this basis, 
adopters can be early adopters or late adopters. Early 
adopters are those who possess high demand for the 
innovation but are relatively cost insensitive but quality 
dependent. In the view of qualitative superiority, these 
early adopters procure the innovation from large firms 
which in turn operate to satisfy the demand of these 
early adopters. In the process of evolving to meet the 
demand of this subset of adopters, the demand of rest 
majority of the market remains unmet. This creates a 
gap between the performance of the innovation and the 
expectations of majority of the market. Realising this 
discrepancy, other firms introduce products based on 
similar principle, with limited scope and quality with 
near equal performance which meets the expectations of 
rest of the market. The original frontier innovation then 
undergoes further refining towards sustained develop-
ment and is called a sustaining innovation. The product 
that was introduced later in the market created by sus-
taining innovation is called a disruptive innovation. 
Competitively promoting both innovations over time 
will result in the introduction of newer technologies 
with superior quality and better performance with re-
duced costs [2]. 
Healthcare Commercialisation Programs and Ven-
ture Capital investment 
Healthcare Commercialisation Programs address the 
major obstacle in the development of innovation by 
bridging the valley of death which spans between the 
emergence of an innovation in academia to the commer-
cialisation of the technology or product. Many academic 
researchers remain unmotivated to carry their work be-
yond their laboratory owing to commercial issues and 
market risks [8]. They assume that publication of the 
details of innovation in a standard high impact journal 
will shift the attention of industry who then go ahead 
with translation. The unwillingness of capitalists to in-
vest on novel innovation is because of unpredictable 
factors like social acceptance, regulatory approval, and 
market value. Instead, they find it safer to invest on 
technologies or product that already exists in the market 
and have proven to be profitable. Healthcare Commer-
cialisation Programs enable and strengthen the innova-
tors to advance their innovations towards commerciali-
sation and entrepreneurial activity by educating and 
enabling them to understand, anticipate, endure and to 
address challenges during commercialisation. HCPs can 
be provided in form of simple webinars, workshops, 
online courses, short-term training courses or special-
ised university programs. Encouraging public invest-
ment and funding to on-demand assuring innovations 
will enhance innovation assimilation. Forming acceler-
ated innovation regulatory bodies that can provide mate-
rial assistance, project facilitation, skill enhancement 
and guidance in academic-industrial collaboration and 
policy making at an accelerated rate for promising inno-
vations will yield higher commercialisation rates. 
Innovation infrastructure and Health Technology 
Assessment 
Health Technology assessment is a significant requisite 
for the introduction of any new product in the healthcare 
market. Health Technology assessment is defined as the 
“systematic evaluation of the properties and effects of a 
health technology as well and it’s indirect and intended 
consequences, and aimed mainly at informing decision 
making regarding health technologies” [9]. A healthy 
interaction among bodies responsible for technology 
assessment, delivery and regulation will hasten the pro-
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 cess of innovation development and translation. The 
absence of a stable health technology assessment pro-
cess, efficient regulatory policies, evidence based opera-
tional guidelines and limited public involvement and 
investment are major hindrances to the development and 
translation of innovations. Owing to the lack of a recog-
nised, stable technology assessment and regulatory body 
in India, the innovators seek the approval of internation-
al regulatory agencies like WHO, FDA and CE which 
impose excessive regulation with standards insensitive 
to domestic context. Formulating precise regulations to 
streamline the process of innovation development is 
essential. Recruiting proficient, and competent regulato-
ry body composed of qualified, skilful multi-
disciplinary experts capable of monitoring and evaluat-
ing the development of innovation needs to be empha-
sised. Close monitoring and periodic evaluation of inno-
vations throughout the process of development and pub-
lishing consensual evaluation report and recommenda-
tions will enhance diffusion, early adoption and will 
drive further research. Moreover, the regulatory bodies 
are expected to provide guidance regarding the develop-
ment and further proceedings on stepwise basis. Regula-
tion of private sector by framing national guidelines is 
also necessary.  Policies and regulations should also be 
framed at the concern of protecting, preserving and re-
specting intellectual property rights of the innovators to 
enhance the interest and involvement of stakeholders. 
Innovation surveillance and Regulation 
Innovation surveillance begins from the time of concep-
tion of novel ideas. Innovation surveillance should be 
under the direct supervision and command of a hierar-
chy of local, regional and national registries. These sur-
veillance registries should perform a close monitoring 
of the process of innovation and translation. A team of 
experts in the apical surveillance body perform continu-
ous research and analysis to recognise the healthcare 
need which is then propagated throughout the academic 
and industrial sectors to device novel modalities to ad-
dress those needs. In certain circumstances, owing to a 
high public health demand for a particular intervention, 
the government or the apical surveillance body should 
entrust a specific public or private organisation for an 
immediate advanced intervention. The proposed novel 
ideas are then critically analysed and appraised. Neces-
sary suggestions and guidance should also be provided 
for promising ideas. It should also be ensured that the 
research organisation is provided with adequate finan-
cial sanctions to generate valid proof of concept, the 
process of which should be closely monitored. Follow-
ing the generation of proof of concept, the expert team 
again evaluates the proof for validity, coherence, adapt-
ability and utility. It also performs predictive analysis 
and cost analysis using standard and plausible statistical, 
mathematical, scientific and business models. The sur-
veillance body also renders sufficient guidance and in-
centives for commercialisation and health technology 
assessment. The local surveillance registries periodical-
ly evaluate the innovation throughout the process of 
development. The regional agencies collect, analyse and 
then relay information to the apical national centre 
where the information is further critically analysed and 
a periodic consensual evaluation report is published. 
These evaluation reports will enable early adoption and 
enhance diffusion. The information is then integrated to 
draft policies and algorithms on effective exploitation of 
the technology. Active feedback mechanisms should 
also be devised to ensure perpetual innovative efforts. 
Development failure and Precision medicine 
Development failure of drug in spite of extensive invest-
ment and huge failure costs account for wastage of re-
sources. Drugs or technologies that might prove effica-
cious and potent in pre-clinical and clinical evaluation 
fail to demonstrate superiority in comparative analysis 
with existing drugs or technology as per the requirement 
of regulatory agencies. Precision medicine is a computa-
tional-knowledge network based modality which is 
based on the basic solid mechanisms and principles of 
disease, diagnosis and therapy. The knowledge network 
integrates biological, medical, scientific, clinical, social 
and behavioural information that enables specific, tar-
geted and efficient innovation development [10]. Inte-
grating diagnostic, molecular and clinical information 
will aid in choosing appropriate therapy and will also 
enable identification people at risk of developing certain 
diseases. Identification of people at risk will enable 
healthcare professionals to implement prevention 
measures, and will also enable early diagnosis and treat-
ment thereby enhancing longevity and quality of life. 
Digitalising healthcare sector, generating reliable evi-
dence to support the superiority of Precision medicine, 
reining data-sharing, incorporating genetic and molecu-
lar data in routine medical practice, attending to the 
infrastructural requirements would be the initial steps 
ahead. 
Contextual mismatch and Local innovation 
Majority of the medical devices used in India are im-
ported from industrialised nations. Almost 75 percent of 
medical devices are purchased from abroad every year 
[11]. These technologies designed to operate in a con-
text of high-resource industrialised environment are 
usually maladapted to resource limited developing envi-
ronment. This is due to lack of local innovation which is 
a direct reflection of the scientific and innovative apti-
tude and competence of education system.  Developing 
markets serve as potential target opportunities for in-
vestment to the investors from developed countries. 
Hence, the countries with limited resources depend on 
the developed nations. It has also been observed that 
majority of the imported medical technologies remain 
idle or are being suboptimally or inappropriately uti-
lised. Measures to enhance the diffusion of imported 
technology, to address the lack of local innovations and 
to redesign imported technologies and devices to adapt 
to Indian operational environment would be the imme-
diate future measures.  
Post-adoption analysis and User-directed innovation 
Rate of innovation is proportional to the availability of 
resources and delivery of healthcare. Adoption is not the 
end of an innovation-translation cycle. Rather it is be-
ginning of User-directed evaluation, feedback, refining, 
redesigning and adaptation. Post-adoption analysis and 
feedback are major drives for subsequent redesigning 
and innovation. Post-adoption feedback is a significant 
tool to understand the demands of the healthcare profes-
sionals which in turn is the reflection of public health 
needs. Post-adoption analysis throws a clear picture of 
the specific demands of the users. Users themselves 
redesign and refine the technology to enable contextual 
adaptation. The healthcare professionals are in direct 
contact with the patients and hence possess better under-
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 standing of the exact demand. Having understood the 
demand, and correlating the demand with the existing 
technology, healthcare professionals are at a position to 
recognise the gap between the expectation and the per-
formance of existing technology. This further drives the 
user-directed innovations to bridge the gap. Hy-
droxychloroquine, a compound which was initially in-
troduced into the market as an antimalarial then proven 
to possess anti- rheumatoid property is now being used 
in the treatment of sulfonylurea-resistant type 2 diabetes 
mellitus [12]. This is an example of User-directed inno-
vation where users explore newer indications and uses. 
The relation between oral contraceptive usage and 
thromboembolic state was a result of post-adoption 
analysis which further lead to the development of low-
dose estrogen pills. It is clear that the first class of inno-
vation is usually never optimal. It needs further refining 
and incremental improvements to ideally meet the de-
mand. Hence, standard systematic feedback mecha-
nisms, user networks and user-developer collaboration 
are significant. 
Co-evolution and Re-establishing the equilibrium 
The currents practices and existing technologies in clini-
cal medicine are at a state of equilibrium which will be 
disturbed by the introduction of an innovation. In this 
state of equilibrium the introduction of an innovation 
needs time and efforts. Measures should be taken to 
disrupt this equilibrium while maintaining the funda-
mental principles of practice and safety and also to en-
sure rapid reestablishment of new state of equilibrium. 
Efforts should be directed towards co-evolution- evolu-
tion of aptitude, medical practice and industrial partici-
pation at a same pace. Over or under performance of 
any one of these factors will disturb the equilibrium. 
Significant measures to improve the aptitude and skills 
of medical professionals to suit the innovation is the 
foremost requirement. This would be possible by revis-
ing the standard of medical education;  expanding the 
scope of medical education to recognise the healthcare 
demands, to explore the available options and to en-
hance the exposure to advanced healthcare technologies; 
familiarising the process of innovation-translation and 
challenges and by promoting research activities among 
medical students. Improving the aptitude of medical 
professionals will revolutionise the practice of clinical 
medicine and will inculcate the significance of innova-
tion and sustained development. 
Conclusion   
Innovation-translation cycle is a dynamic sequence of 
complex events that demand multi-disciplinary interac-
tion, development, evaluation, adoption, feedback and 
renovation which is better explained by Self-
perpetuating non-linear Cyclic dynamic model. Formu-
lating a new multi-pronged, multi-faceted initiative that 
ensures favourable political climate, adequate human 
and material resources, efficient commercialisation, 
meticulous surveillance, conducive regulation and oper-
ation policies, appropriate context of utilisation, system-
atic post-adoption analysis and feedback mechanisms 
and co-evolution of the academia, industry, user and the 
environment of exploitation would be the ideal strategy 
to promote innovation-translation. 
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